Resultados visuales en pacientes con macroprolactinoma tratados con agonistas de dopamina
Author
dc.contributor.author
Cuevas, José Luis
Author
dc.contributor.author
Fernández, Verónica
es_CL
Author
dc.contributor.author
Rojas, David
es_CL
Author
dc.contributor.author
Wohllk González, Nelson
es_CL
Author
dc.contributor.author
González, Óscar
es_CL
Author
dc.contributor.author
Torche, Esteban
es_CL
Admission date
dc.date.accessioned
2014-03-13T14:28:40Z
Available date
dc.date.available
2014-03-13T14:28:40Z
Publication date
dc.date.issued
2013
Cita de ítem
dc.identifier.citation
r ev Med Cchile 2013; 141: 687-694
en_US
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/129313
General note
dc.description
Artículo de publicación ISI
en_US
Abstract
dc.description.abstract
Background: Dopamine agonists (DA) effectively reduce tumor size of macroprolactinomas,
with the consequent improvement of eventual visual impairment. Aim: To study the visual outcomes in patients with macroprolactinoma treated with DA. Material and Methods: Retrospective cohort study which included patients with macroprolactinoma controlled at a Neuroendocrinology and Neuroophthalmology Department between 1997 and 2011, and treated exclusively with DA (bromocriptine or cabergoline). Patients who were operated or had previous radiotherapy and those with an incomplete follow up, were excluded. We analyzed and compared the visual status before and after the beginning of DA treatment. Results: Thirty one patients aged 8 to 59 years, were included. Eighteen patients (58%) had visual impairment at the moment of diagnosis (group 1) and 13 had no alterations (group 2). Mean follow up was 36.5 months. Fifteen patients from group 1 (83%) had visual improvement, two remained stable (11%) and one had a visual deterioration (6%). In group 2, only one non-compliant patient had a visual deterioration. Conclusions: DAs are effective in the management of neuro-ophthalmic complications associated to macroprolactinomas
and should be considered as first choice therapy in these tumors.